2-(溴甲基)-5-氯-1-苯并噻吩 | 99592-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 2-(溴甲基)-5-氯-1-苯并噻吩
• 英文名称: 2-(bromomethyl)-5-chlorobenzo[b]thiophene
• 英文别名: 2-(Bromomethyl)-5-chloro-1-benzothiophene
• CAS: 99592-53-7
• 化学式: C₉H₆BrClS
• mdl: MFCD16622781
• 分子量: 261.57
• InChiKey: VTQJFFDCDCIHAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-5-氯-1-苯并噻吩 在 吡啶 、 氢氧化钾 、 氯化亚砜 、 盐酸羟胺 、 sodium methylate 、 四丁基硫酸氢铵 作用下， 以 甲醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 19.83h， 生成 4-[(5-chloro-2-benzo[b]thienyl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide
  参考文献：
  名称：

  Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).

  DOI：

  10.1021/jm00085a002
• 作为产物：
  描述：

  5-chloro-2-methylbenzo[b]thiophene 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以38%的产率得到2-(溴甲基)-5-氯-1-苯并噻吩
  参考文献：
  名称：

  卤素取代的 2- 和 3-甲基苯并[b] 噻吩：使用 1H NMR 光谱分析和 1H{1H} 核 Overhauser 效应定位卤素取代基

  摘要：

  制备了 37 个卤代 2- 和 3-甲基-（或卤甲基）-苯并 [b] 噻吩，包括 17 个新化合物。通过对它们的 80 MHz 1 HNMR 光谱的全面分析 (LAOCOON) 和 1H{1H} NOE 测量，证实了其中 14 种的构成。通过这种方式，4-和6-溴-3-溴甲基苯并[b]噻吩的制备副产物最终显示为5-溴-3-溴甲基苯并[b]噻吩。当照射 3-甲基或卤代甲基取代基时，3-取代的苯并[b]噻吩在 H-4 处显示出比在 H-2 处更大的 NOE 增强因子。

  DOI：

  10.1002/mrc.1260231006

文献信息

• [EN] N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：BIOMARIN PHARM INC

  公开号：WO2015065937A1

  公开（公告）日：2015-05-07

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本处描述的是公式I的化合物，制造此类化合物的方法，包含此类化合物的药物组合物和药品，以及用于治疗或预防与葡萄糖苷鞘氨醇合酶（GCS）相关疾病的I化合物。
• Hypoglycemic imidazoline compounds
  申请人：ELI LILLY AND COMPANY

  公开号：EP1266897A3

  公开（公告）日：2003-12-03

  This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.The compounds have the following formula: whereinX is -O-, -S-, or -NR5-;R5 is hydrogen, C1-8 alkyl, or an amino protecting group;R4 isY is -O-, -S-, or -NR8-;Y' is -O- or -S-;

  本发明涉及某些新型的咪唑啉化合物及其类似物，以及它们用于治疗糖尿病、糖尿病并发症、代谢紊乱或相关疾病中的糖利用受损情况，涉及包含它们的药物组合物，以及它们的制备过程。这些化合物的公式如下：其中X是-O-，-S-，或-NR5-；R5是氢，C1-8烷基，或氨基保护基团；R4是Y是-O-，-S-，或-NR8-；Y'是-O-或-S-；
• Nickel‐Catalyzed 1,1‐Alkylboration of Electronically Unbiased Terminal Alkenes
  作者：Yangyang Li、Hailiang Pang、Dong Wu、Zheqi Li、Wang Wang、Hong Wei、Ying Fu、Guoyin Yin

  DOI：10.1002/anie.201903890

  日期：2019.6.24

  electronically unbiased alkenes has been developed, providing straightforward access to secondary aliphatic boronic esters from readily available materials under very mild reaction conditions. The regioselectivity of this reaction is governed by a unique pyridyl carboxamide ligated catalyst, rather than the substrates. Moreover, this transformation shows excellent chemo‐ and regio‐selectivity and remarkably

  已经开发出前所未有的镍催化的电子无偏烯烃的1,1-烷基硼化，可在非常温和的反应条件下直接从易得的材料中获得仲脂族硼酸酯。该反应的区域选择性由独特的吡啶基羧酰胺连接的催化剂而不是底物决定。此外，这种转化还显示出优异的化学和区域选择性以及出色的功能基团耐受性。我们还证明了在气球压力下，乙烯也可以用作底物。此外，能力实验表明，在硼的α位有利于选择性键的形成，初步的机理研究表明，这种三组分反应的关键步骤涉及1,2-镍的迁移。
• Benzimidazole-derivatives as factor Xa inhibitors
  申请人：Nazare Marc

  公开号：US20050009829A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of the formula I, wherein R 0 , R 1 , R 2 , Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0、R1、R2、Q、V、G和M如本文所定义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，适用于心血管疾病如血栓栓塞病或再狭窄的治疗和预防。它们是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可以应用于存在因子Xa和/或因子VIIa的不良活性或者需要抑制因子Xa和/或因子VIIa以治疗或预防的情况。此外，本发明还涉及制备式I的化合物的方法，它们的使用，尤其是作为药物的活性成分，以及包含它们的制药制剂。
• Use of GAL3 antagonist for treatment of depression
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040127502A1

  公开（公告）日：2004-07-01

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  本发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。本发明提供一种包含本发明化合物的治疗有效量和药学上可接受的载体的制药组合物。本发明还提供一种由本发明化合物的治疗有效量和药学上可接受的载体组合而成的制药组合物。本发明还提供一种制备包括本发明化合物的治疗有效量和药学上可接受的载体的制药组合物的方法。本发明还提供一种治疗患有抑郁症和/或焦虑症的受试者的方法，该方法包括向受试者施用本发明化合物的治疗有效量以治疗受试者的抑郁症和/或焦虑症。本发明还提供一种治疗受试者抑郁症和/或焦虑症的方法，该方法包括向受试者施用一种包含药学上可接受的载体和GAL3受体拮抗剂的治疗有效量的组合物。